Genmab A/S
GMAB22.025USD
+0.245+1.12%
시장 운영 시간 （ET）시세는 15분 지연됩니다
1.40B시가총액
0.41P/E TTM
자세한 내용은 Genmab A/S 회사
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
회사 정보
종목 코드 GMAB
회사 이름Genmab A/S
상장일Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
직원 수2682
유형Ordinary Share
회계 연도 종료Oct 01
주소Carl Jacobsens Vej 30
도시VALBY
증권 거래소OMX Nordic Exchange Copenhagen A/S
국가Denmark
우편 번호2500
전화4570202728
웹사이트https://www.genmab.com/
종목 코드 GMAB
상장일Oct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
데이터 없음
사업별
지역별
사업별USD
이름
수익
비율
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
주주
주주
비율
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
4.27%
Investment Advisor
2.99%
Hedge Fund
2.45%
Research Firm
0.51%
Pension Fund
0.03%
Bank and Trust
0.02%
Venture Capital
0.01%
Other
89.73%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
498
64.99M
10.26%
-6.57M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
2023Q1
481
44.22M
6.78%
-6.32M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
AllianceBernstein L.P.
14.73M
2.32%
-210.07K
-1.41%
Mar 31, 2025
Orbis Investment Management Ltd.
5.71M
0.9%
+2.90M
+102.83%
Mar 31, 2025
Citadel Advisors LLC
4.43M
0.7%
+1.33M
+43.16%
Mar 31, 2025
Two Sigma Investments, LP
3.87M
0.61%
+513.60K
+15.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.95M
0.47%
-433.32K
-12.82%
Mar 31, 2025
Harding Loevner LP
2.88M
0.45%
+637.43K
+28.41%
Mar 31, 2025
Renaissance Technologies LLC
2.26M
0.36%
+336.20K
+17.45%
Mar 31, 2025
Marshall Wace LLP
2.18M
0.34%
+1.06M
+94.38%
Mar 31, 2025
Brandywine Global Investment Management, LLC
1.72M
0.27%
+97.63K
+6.03%
Mar 31, 2025
First Trust Advisors L.P.
1.71M
0.27%
+65.52K
+3.98%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Tema Oncology ETF
3.66%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
WisdomTree BioRevolution Fund
0.99%
iShares Biotechnology ETF
0.87%
First Trust NASDAQ BuyWrite Income ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
Avantis International Equity ETF
0.07%
ActivePassive International Equity ETF
0.07%
Avantis International Large Cap Value ETF
0.05%
더 보기
Tema Oncology ETF
비율3.66%
First Trust NYSE Arca Biotechnology Index Fund
비율3.45%
WisdomTree BioRevolution Fund
비율0.99%
iShares Biotechnology ETF
비율0.87%
First Trust NASDAQ BuyWrite Income ETF
비율0.2%
ProShares Ultra Nasdaq Biotechnology
비율0.1%
Invesco Nasdaq Biotechnology ETF
비율0.1%
Avantis International Equity ETF
비율0.07%
ActivePassive International Equity ETF
비율0.07%
Avantis International Large Cap Value ETF
비율0.05%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
